Latest Boardroom Shifts News

Mach7 Technologies has updated its FY25 guidance, reporting positive cash flow and a solid financial position, while appointing Teri Thomas as its new CEO to steer the company’s next growth phase.

Mach7 Technologies closes FY25 with solid recurring revenue growth, positive cash flow, and a refreshed leadership team focused on innovation and customer value.

Advanced Braking Technology Ltd (ABT) posted a robust FY25 with sales up 27% and underlying profits nearly doubling, driven by strong international demand and innovation milestones.

Resolute Mining reported solid Q2 2025 gold production of 75,962 ounces and maintained its full-year guidance, supported by strategic project acquisitions and steady progress across key West African assets.

Wisr Limited has reported a standout Q4FY25 with loan originations soaring 154% year-on-year, surpassing its full-year guidance and showcasing improved credit quality.

Piche Resources has appointed Karilyn Farmer as Managing Director, signaling a strategic push for its gold and uranium assets as founder Stephen Mann retires.

Corazon Mining has completed the sale of its remaining interest in the Miriam Project, appointed Simon Coyle to its board, and continues to push exploration in Canada and Australia amid a strategic review.

Richmond Vanadium Technology has paused parts of its feasibility study and approval processes in response to a prolonged downturn in vanadium prices, focusing instead on metallurgical innovation and cash conservation.

Peninsula Energy advances commissioning at its Lance uranium project, resets most sales contracts to reduce risk, and secures a $15 million debt facility to support production ramp-up.

Canyon Resources has achieved critical milestones for its Minim Martap Bauxite Project, including port access approval and a substantial credit facility, setting the stage for production and first shipment in early 2026.

Alkane Resources secured shareholder approval for its merger with Mandalay Resources, marking a pivotal step toward creating a combined gold and antimony producer. The transaction awaits final court confirmation in Canada.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.